Direction
Infrastructure and clinic
Cell atlases, shared datasets, laboratory instruments and ways to deliver therapies make the other approaches possible. The field also needs people, institutions and clinical pathways that turn discoveries into work others can build on.
The next question
Can another lab reproduce and build on the result?
Inside the researchOpen cell atlas
The Tabula Muris project published a shared resource of more than 100,000 cells from twenty mouse organs and tissues. It lets researchers compare cell types across the body using common reference data.
What this leaves open. An atlas is a research tool, not a treatment. Its value depends on how well new experiments can use and extend it.
Read the paper ↗Single-cell transcriptomics of 20 mouse organs creates a Tabula MurisTabula Muris Consortium · Nature · 2018Side by side
The rated projects, compared
| Project▲ | Promised effect▲ | Evidence▲ | Stage▲ | Strongest case against▲ |
|---|---|---|---|---|
| DTL | +0.5 years of life | The evidence base is mostly product positioning: the DTL page claims coverage of 700+ longevity biotech companies, 3,100+ drug assets, 14 domains, continuous monitoring, reports, and traceable copilot answers. | Appears active as of 2026, with a live product page, contact/demo flow, custom-report offering, and a publicly announced strategic partnership with AND Capital Ventures. | The main failure mode is that DTL is mostly packaging: a marketing-led aggregation product without defensible data quality, differentiated insight, or measurable decision advantage over generic research workflows and incumbent intelligence platforms. |
| First Approval | +0.5 years of life | The project-specific evidence base is mostly platform and competition copy. | The project looks pre-scale but active. | The failure case is straightforward: this may be mostly packaging around a familiar open-science problem without proving that researchers will change behavior. |
| NUS Academy for Healthy Longevity | +1.5 years of life | The evidence base is credible for field-building and measurement, weaker for intervention efficacy. | Operational but early. | The project could stall as a well-branded but weakly validated platform if biomarker-guided personalization does not translate into robust human benefit, if single-arm multimodal studies remain too confounded to interpret, or if supplement- and partnership-driven narratives outpace regulation and evidence. |
| Pentara Brain Stride | +0.5 years of life | There is relevant background evidence that optimized cognitive endpoints and enrichment strategies matter in Alzheimer's and preclinical AD studies, including longitudinal cohort analyses and endpoint-methodology work. | The project appears to be an operating company service rather than an early concept. | The project may amount to a strong specialist CRO-style service with good positioning but limited proof of differentiated outcomes. |
| R42 Group | +1.5 years of life | The strongest project-specific evidence supports R42 as an active funder and venture platform, not as a validated scientific program. | Active but weakly validated. | R42 may also be mostly narrative. |
| Singularis: reforming the communication of scientific knowledge | The claimed effect could be meaningful: faster navigation of hypotheses, experiments, results, conclusions, and evidence than reading narrative papers. | There is a visible beta product page and a team-authored project description, plus field-context literature showing that linked research, continuous publishing, computable knowledge, and agent-native research artifacts are active areas. | Early stage and beta. | The project may stall because the hard part is not just graph technology but institutional adoption, annotation accuracy, and migration of legacy literature; without strong precision, clear user advantage, and integration into existing evaluation systems, it risks remaining an interesting beta visualization layer on top of papers rather than changing scientific communication. |
Companies
Companies in this direction
Ambition is what a company claims. Independent replication is what others have confirmed. Read the two columns together: the gap between them is where a promise runs ahead of a result.
| Company▲ | Ambition▲ | Independent replication▲ | Stage▲ | Headquarters▲ |
|---|---|---|---|---|
| Ani Biome ANI Biome builds autonomous intelligence for human biology and longevity medicine using multiomics, digital phenotyping, and physician-supervised intervention. | 7 | 1 | – | San Francisco, California |
| AVEA AVEA develops science-backed longevity supplements for energy, sleep, skin, gut, glucose metabolism, and healthy ageing. | 6 | 2 | – | Berlin, Germany |
| Healome Healome is an AI health coach to track and slow biological age. | 6 | 1 | – | Hyderabad, India |
| Humanity Inc Humanity is an app that monitors rate of aging and helps users identify actions to improve healthspan. | 6 | 0 | – | United Kingdom |
| Magnitude Biosciences Magnitude Biosciences provides customised C. elegans studies and whole-organism high-throughput screening for research areas including ageing, neurodegeneration, toxicity, and gut health. | 6 | 4 | – | United Kingdom |
| Minicircle Minicircle offers non-viral plasmid gene therapy for longevity, performance, wellness, and body-composition benefits. | 7 | 1 | – | – |
| OneSkin Technologies OneSkin develops topical OS-01 peptide products for healthy skin aging and cellular senescence reduction. | 6 | 2 | – | San Francisco, California, United States |
Projects
Projects in this direction
| Project▲ | Stage▲ | Strongest case against▲ |
|---|---|---|
| Beat-FSHD Beat-FSHD appears to be a patient-facing FSHD support, education, advocacy, and news website rather than a research or therapeutic program. | Project status is difficult to rate highly from the provided evidence. | The project may simply be an underdeveloped or placeholder website with weak editorial controls and unclear ownership. |
| DTL DTL appears to be a UK-based longevity market-intelligence product from First Longevity / Longevity.Technology, positioned as an AI-enabled, structured data and analysis layer over longevity biotech companies, drug assets, and related signals such as trials, financing, IP, partnerships, and talent. | Appears active as of 2026, with a live product page, contact/demo flow, custom-report offering, and a publicly announced strategic partnership with AND Capital Ventures. | The main failure mode is that DTL is mostly packaging: a marketing-led aggregation product without defensible data quality, differentiated insight, or measurable decision advantage over generic research workflows and incumbent intelligence platforms. |
| First Approval First Approval appears to be an early-stage scientific data publishing platform for biology and longevity-adjacent research, centered on structured dataset annotation, decentralized/encrypted storage, customizable licensing, DOI-linked publication, and incentive mechanisms for sharing. | The project looks pre-scale but active. | The failure case is straightforward: this may be mostly packaging around a familiar open-science problem without proving that researchers will change behavior. |
| FuturVille FuturVille is a for-profit Canadian project positioning itself as a builder of "healthy longevity villages," with VulcanVille in Vulcan, Alberta presented as the first prototype: a 53-63 acre mixed-use site with 300+ dwelling units, wellness and retreat facilities, commercial space, and related development/investment offerings. | Early commercial development and branding stage. | The more likely failure mode is that FuturVille remains a promotional wellness-real-estate concept with overstated health claims, weak scientific grounding, limited execution capacity, and no credible evidence that its village model adds measurable healthy years beyond standard amenity-driven community living. |
| Gobal Health Span Extension Global Health Span Extension appears to be a Felix Platter-affiliated healthy-aging/healthspan initiative or consortium, but the direct project evidence is thin: the Felix Platter site mainly shows a navigation-level reference to a “Global Health Span Extension Consortium” rather than a substantive project description. | Project status is unclear from the direct Felix Platter evidence. | The main downside case is that this is more branding and consortium framing than demonstrated project substance: the direct evidence for the project itself is sparse, the strongest adjacent evidence is still only partially visible from titles/metadata in several cases, and even positive DO-HEALTH-style signals may prove modest, population-specific, or insufficient to justify broad claims about extending healthspan. |
| Healthspan Quest Healthspan Quest appears, on the available evidence, to be a Valley Christian Schools student team in the 2024-25 XPRIZE Healthspan competition rather than a validated longevity research program or venture. | Earliest reliable status is that Healthspan Quest was presented by Valley Christian Schools as a 2024-25 XPRIZE Healthspan team and reported as Top 100. | The more likely interpretation from current evidence is that Healthspan Quest is mainly a school-branded competition team with aspirational longevity language and little verifiable substance yet. |
| NUS Academy for Healthy Longevity The NUS Academy for Healthy Longevity appears to be a Singapore-based precision-geromedicine hub at NUS that combines clinical-trial infrastructure, biomarker-oriented research, education, and public-facing convening around healthy longevity. | Operational but early. | The project could stall as a well-branded but weakly validated platform if biomarker-guided personalization does not translate into robust human benefit, if single-arm multimodal studies remain too confounded to interpret, or if supplement- and partnership-driven narratives outpace regulation and evidence. |
| Pentara Brain Stride Pentara Brain Stride appears to be a clinical-trial biostatistics and data-integrity offering focused on neurodegenerative disease studies, especially regulatory-facing trial design, analysis, and fraud detection. | The project appears to be an operating company service rather than an early concept. | The project may amount to a strong specialist CRO-style service with good positioning but limited proof of differentiated outcomes. |
| R42 Group R42 Group appears to be a U.S.-based, founder-led venture platform and family-office-derived group centered on AI, biotech, and longevity, with an adjacent education/community arm (R42 Institute). | Active but weakly validated. | R42 may also be mostly narrative. |
| Singularis: reforming the communication of scientific knowledge Singularis is an early-stage scientific-knowledge platform that argues conventional papers are a bottleneck for both human readers and AI systems, and proposes converting papers into structured argumentation graphs and nanopublication-like units that link hypotheses, methods, results, conclusions, and evidence. | Early stage and beta. | The project may stall because the hard part is not just graph technology but institutional adoption, annotation accuracy, and migration of legacy literature; without strong precision, clear user advantage, and integration into existing evaluation systems, it risks remaining an interesting beta visualization layer on top of papers rather than changing scientific communication. |
| Team NovaVita Available evidence does not substantiate Team NovaVita as a distinct longevity project. | Status is unclear and low-confidence. | The more likely interpretation is identity mismatch: “Team NovaVita” appears to be a student leadership or branding label, while the longevity-related patent and PKU materials are generic field context with no verified connection to the project. |
People
People in this direction
- George Churchscientist · through Colossal
Led and founded major synthetic biology and genomics efforts with public work on aging reversal, gene therapy, and longevity biotechnology companies including Rejuvenate Bio.
- Valter Longoscientist · through Longevity technology
Biogerontologist translating fasting biology into longevity interventions
- Alex Zhavoronkovpopulariser · through Tracked.bio
- João Pedro de Magalhãesscientist · through Senescence.info
Senescence.info founder and aging-database builder.
- Vera Gorbunovascientist · through DoNotAge
Biologist discovering natural mechanisms of cancer resistance and longevity
- Matt Kaeberleinscientist · through NOVOS Labs
- Leonard Guarentescientist · through Elysium Health
MIT aging researcher whose lab helped establish sirtuins and metabolic regulation as major longevity mechanisms; founder of Elysium Health.
- Eric Verdinscientist · through Elevant
- Nir Barzilaiscientist · through Longevity technology
- Gregory Fahyscientist · through Organ Preservation Alliance
Cryobiologist pioneering thymus regeneration and immune rejuvenation
- Kristen Fortneyentrepreneur · through Humanity Inc
- Anar Ismanentrepreneur · through AgelessRx
- Bryan Johnsonself experimenter · through Minicircle
- Nathan Chengpopulariser · through Longevity List
- David Sinclairscientist · through Longevity List
- Peter Diamandisentrepreneur · through Fountain Life
- Phil Newmanpopulariser · through Longevity technology
- Sam Altmaninvestor · through Longevity technology
Chronology
What happened, and when
Forecasts
What the forecasts expect here
- In which year will a startup working on morphogenetic approaches to defeating aging reach a $300M+ valuation?14% yesby Nov 1, 2026
- How many deals or partnerships with an upfront payment over $500M on aging-biology assets will happen from Jul 2026 to Jul 2027?17% yesby Nov 1, 2026
- When will the first longevity company reach a $10B+ valuation?17% yesby Nov 1, 2026
- How big will Altos Labs' next round be?14% yesby Nov 1, 2026
- When will artificial electrical synapses (Duke LinCx) or connectome-based activity prediction (Eon) reach first human use?17% yesby Nov 1, 2026
- When will a FutureHouse Robin-style multi-agent system produce a candidate that reaches clinical trials?17% yesby Nov 1, 2026
- When will Anthropic's first clinical phase begin?14% yesby Nov 1, 2026
This month
Reported recently
- The World's Largest Atlas of Cancer Cell Drug Responses Passes Peer Review and Appears in CellSep 22, 2026Tahoe-100M — 100 million single-cell drug-response profiles across 50 cancer lines — passes peer review in Cell and benchmarks AI models for drug-response prediction.
- A hypothesis-free AI screened the medication histories of nearly a million patients and identified varenicline, a smoking cessation drug, as a candidate for dementia prevention. Validation in an independent cohort of 9584 people showed a dementia risk reduction of nearly half compared with nicotine replacement therapySep 22, 2026An AI screened ~1 million patient records and found varenicline, a smoking cessation drug, reduces dementia risk by nearly half versus nicotine replacement therapy.
- MIT identifies a shared chemical fingerprint of cellular aging: a lipid signal identical in mouse lung and skin yields a precise barcode for detecting senescent cells without destroying tissueSep 22, 2026MIT's RamanOmics method detected a shared lipid signal in aging mouse lung and skin, producing a non-destructive barcode that identifies senescent cells more accurately than p21 or p16 alone.
- A new preprint applies AlphaGenome and AlphaMissense to somatic mutations in 8800 patients across 33 cancer types: gene damage from passenger mutations is associated with survival independently of total tumor mutation burdenSep 21, 2026AlphaGenome and AlphaMissense applied to 8800 tumors show that passenger mutation damage predicts survival independently of total mutation burden.
- A diffusion model converts a routine brain MRI into a metabolism map resembling an expensive PET scan and improves dementia diagnostic accuracy in a blinded physician readingSep 21, 2026A TUM diffusion model synthesizes PET-like brain metabolism maps from routine MRI, achieving 85.5% dementia diagnostic accuracy — between MRI (75.8%) and real PET (95.2%).
- A GPT-4o AI agent independently scored the severity of all 10,211 human genetic disease phenotypes from the medical literature, and its list of severe genes matched 95% of the genes in Australia's national carrier screening program Mackenzie's MissionSep 21, 2026A GPT-4o AI agent autonomously scored all 10,211 human genetic disease phenotypes from PubMed, matching 95.2% of Australia's Mackenzie's Mission carrier screening panel at ~$1,000 total cost.
- The generative model LDDM designed binding molecules for five proteins, and X-ray crystallography confirmed its 3D prediction for one targetSep 21, 2026EPFL's LDDM generative model designed synthesizable binding compounds for five target proteins; X-ray crystallography confirmed its predicted pose for the SARS-CoV-2 Mac1 enzyme.
- BCG and Super Human Network Publish the First Industry Benchmark for the Longevity Sector: Over $21 Billion Invested Across Roughly 1,300 Companies, but the Gap Between Total and Healthy Life Expectancy Has Grown from 8.5 to 9.6 YearsSep 21, 2026BCG and Super Human Network release the first longevity industry benchmark: $21B invested across ~1,300 companies, yet years lived in poor health keep rising.